北京招聘

RESPONSIBILITIES

● Project management?: Develop risk management strategies and proactively manage timelines to ensure successful oversight and delivery of studies, projects and coding responsibilities.

●Vendor management:? Partner with relevant functions for external data vendor selection and management, ensuring use of standards, fit-for-purpose data models and transfer intervals.

● Data collection and acquisition: ?Act as experts for data collection, advising teams and stakeholders on best practices and proposing innovative solutions. Ensure a high quality of data and compliance with applicable pharma industry regulations and standards.

● Data quality review?: Use data surveillance tools and strategies to provide aggregate level reviews designed to identify patterns or anomalies in our data to ensure high quality results.

● Support analysis:? Partner with stakeholders to understand their data insight needs and offer Data Management solutions. Demonstrate a strong understanding of the data flow from collection through to analysis and filing.

● Technical consulting: Offer guidance and advice to peers within the function, to key stakeholders and to FSPs, ?CRO and collaborative groups on technical solutions to ensure high quality data collection and delivery. Deliver on solutions as needed.

● Support DM team to implement/setup/application/approval all design of eCRF/EDC.

任职要求：

● MSc degree and above in Life Sciences, medical, Data/Computer Science, Bioinformatics OR equivalent industry experience. Fresh graduates preferred.

● Demonstrated strong collaboration and excellent communication skills – both written and oral (proficiency in English required).

● Experience with data analytics and/or visualization tools and techniques.

● Demonstrated entrepreneurial mindset and self-direction, ability to mentor others and willingness to learn new techniques.

● Knowledge of biological principles, display interest and demonstrate scientific curiosity including an understanding of data types and their scientific use (?clinical, biomarker, etc.).

    迪哲医药的前身为阿斯利康亚洲及新兴市场创新研发中心，设立于中国上海，是阿斯利康全球四个研发中心之一（另三个中心分别位于英国剑桥、瑞典哥德堡、美国盖瑟斯堡）；是国际一流、高产出的创新药研发机构，拥有全球领先的转化医学和新药分子设计与筛选技术平台；在恶性肿瘤、自身免疫性疾病、肾病等重大疾病的新药研究方面积累了丰富经验。
    迪哲医药，于2017年10月独立运营，是一家研发驱动型生物医药企业，致力于全球创新药物（First-in-class/ Best-in-class）探索、研发以及商业化。
    详情请点击公司官方网站：**************************/

Dizal Pharma
On Nov. 27th, 2017, through a joint venture between AstraZeneca and China Advanced Manufacturing Fund, Dizal Pharma was co-constructed as a world-leading innovative bio-pharmaceutical enterprise. As a new, unique mode of cooperation between SDIC Fund Management Company Ltd. and worldwide privileged research resources in the field of biological pharmacy, Dizal Pharma can not only accelerate the launch and listing of global new drugs in China, bring Chinese patients access to the latest drugs found across the world at once and thus raise the clinical benefits of patients; At the same time, we also take advantages of the global privileged innovative resources, increase China’s core competitive power in the innovation of new drugs, step in the leading branch of international research and development of new drugs and push China into the role of causing both huge and powerful influence in pharmacy industry.
As a new-style joint venture company, besides the project of the transfer of AstraZeneca’s patents, Dizal Pharma also develops the innovation and creation of global First-in-Class drugs.
The R&D (Research and Development) team of Dizal Pharma was AstraZeneca Asia and Emerging Market Research Center. As one of AstraZeneca’s first four R&D centers across the world, it dedicated to analyze the potential scientific mechanism of those most common diseases in Asia and fulfill the particular medical needs of Asian patients. It was one of the few R&D centers established by transnational pharmacy enterprises in China which had the ability to actually research, develop and produce micro-molecular new drugs, the ability to develop produce new drugs independently and completely, and the first-class medical platform in the world.